Alamar Biosciences, Inc. (California) (ALMR)
34.36
+1.90
(+5.85%)
USD |
NASDAQ |
Oct 02, 16:00
34.62
+0.26
(+0.76%)
After-Hours: 20:00
Alamar Biosciences Enterprise Value : 2.186B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.186B |
| October 01, 2026 | 2.054B |
| September 30, 2026 | 2.165B |
| September 29, 2026 | 2.067B |
| September 28, 2026 | 2.064B |
| September 25, 2026 | 2.077B |
| September 24, 2026 | 2.105B |
| September 23, 2026 | 2.031B |
| September 22, 2026 | 2.106B |
| September 21, 2026 | 2.233B |
| September 18, 2026 | 2.220B |
| September 17, 2026 | 2.022B |
| September 16, 2026 | 1.840B |
| September 15, 2026 | 1.796B |
| September 14, 2026 | 1.744B |
| September 11, 2026 | 1.737B |
| September 10, 2026 | 1.728B |
| September 09, 2026 | 1.811B |
| September 08, 2026 | 1.880B |
| September 04, 2026 | 1.938B |
| September 03, 2026 | 1.923B |
| September 02, 2026 | 1.917B |
| September 01, 2026 | 1.839B |
| August 31, 2026 | 1.920B |
| August 28, 2026 | 1.932B |
| Date | Value |
|---|---|
| August 27, 2026 | 2.091B |
| August 26, 2026 | 2.166B |
| August 25, 2026 | 2.093B |
| August 24, 2026 | 2.070B |
| August 21, 2026 | 2.177B |
| August 20, 2026 | 2.205B |
| August 19, 2026 | 2.267B |
| August 18, 2026 | 2.088B |
| August 17, 2026 | 2.031B |
| August 14, 2026 | 2.102B |
| August 13, 2026 | 2.086B |
| August 12, 2026 | 2.099B |
| August 11, 2026 | 2.339B |
| August 10, 2026 | 1.744B |
| August 07, 2026 | 1.776B |
| August 06, 2026 | 1.751B |
| August 05, 2026 | 1.768B |
| August 04, 2026 | 1.682B |
| August 03, 2026 | 1.680B |
| July 31, 2026 | 1.561B |
| July 30, 2026 | 1.541B |
| July 29, 2026 | 1.492B |
| July 28, 2026 | 1.516B |
| July 27, 2026 | 1.494B |
| July 24, 2026 | 1.597B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| 10X Genomics, Inc. | 11.71B |
| Personalis, Inc. | 1.557B |
| Adaptive Biotechnologies Corp. | 4.583B |
| Champions Oncology, Inc. | 75.94M |
| Medpace Holdings, Inc. | 16.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.20M |
| Revenue (Quarterly) | 29.43M |
| Total Expenses (Quarterly) | 42.63M |
| EPS Diluted (Quarterly) | -0.1902 |
| Gross Profit Margin (Quarterly) | 60.21% |
| Profit Margin (Quarterly) | -44.85% |
| Earnings Yield | -2.07% |
| Normalized Earnings Yield | -1.772 |